Side-by-side · Research reference
ARA 290vsVIP
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED17/59 cited
BPhase 3HUMAN-REVIEWED9/42 cited
VIP
Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)
IV infusion · Inhaled (investigational)Brown 2023Boesing 2022
01Mechanism of Action
Parameter
ARA 290
VIP
Primary target
Innate repair receptor (EPO receptor / CD131 heterodimer)
VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025
Pathway
EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades
VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection
Downstream effect
Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014Culver 2017
Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration
Feedback intact?
N/A — does not interact with hematopoietic EPO receptorLiu 2014
Yes — exogenous VIP acts as physiological agonist
Origin
11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties
Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP
Antibody development
Not reported in clinical trials
—
02Dosage Protocols
Parameter
ARA 290
VIP
Standard dose (Phase 2)
4 mg / dayBrines 2015Culver 2017
Sarcoidosis SFN and diabetic neuropathy trials.
—
Frequency
Once daily
Self-administered subcutaneously.
—
Evidence basis
Phase 2 RCTsCulver 2017Brines 2015
64-subject sarcoidosis trial, type 2 diabetes trial.
Phase 3 RCT (TESICO)Brown 2023
816-patient randomized controlled trial in COVID-19 ARDS.
Timing
Any time of day
No circadian dependence reported.
—
Intravenous (ARDS protocol)
—
60–90 mcg/kg/day via continuous infusion
TESICO trial protocol for COVID-19 ARDS.
Inhaled (investigational)
—
Variable dosing under clinical trial protocolsBoesing 2022
Delivered via nebulizer for direct pulmonary deposition.
Treatment duration
—
3–14 days (acute ARDS)
Reconstitution
—
Lyophilized powder reconstituted with sterile diluent per protocol
Half-life
—
~2 minutes (plasma)
Rapid clearance necessitates continuous infusion.
03Metabolic / Fat Loss Evidence
Parameter
ARA 290
VIP
Primary effect
Improved metabolic control (HbA1c, fasting glucose)Brines 2015
Secondary to neuropathy treatment; direct lipolytic effects not established.
—
HbA1c
Significant reduction vs placebo
Observed in type 2 diabetes + neuropathy trial.
—
Fasting glucose
Improved in ARA 290 group
—
Body composition
Not directly quantified
Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.
—
04Side Effects & Safety
Parameter
ARA 290
VIP
Injection site reaction
Mild, transient
—
Hematopoiesis
None — non-erythropoietic
Distinguishes ARA 290 from native EPO.
—
Cardiovascular
No thrombotic events or hypertension reported
—
Immunogenicity
No antibody formation reported
—
Hypotension
—
Transient vasodilation-related blood pressure drop
Tachycardia
—
Reflex tachycardia secondary to vasodilation
Infusion site reactions
—
Erythema, phlebitis (IV administration)
GI symptoms
—
Nausea, diarrhea (VIP is endogenous GI peptide)
Overall tolerability
—
Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo
Absolute Contraindications
ARA 290
- ·Hypersensitivity to ARA 290
VIP
- ·Known hypersensitivity to aviptadil or formulation components
Relative Contraindications
ARA 290
- ·Active malignancy (theoretical EPO-axis concern; not observed in trials)
VIP
- ·Severe hypotension or shock states (monitor blood pressure)
- ·Pregnancy — insufficient safety data
05Administration Protocol
Parameter
ARA 290
VIP
1. Preparation
Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.
Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.
Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).
3. Timing
Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015
Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.
4. Dosing
4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017
Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.
5. Storage
Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.
Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.
06Stack Synergy
ARA 290
+ BPC-157
ModerateARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.
- ARA 290
- 4 mg SQ · daily
- BPC-157
- 250–500 mcg SQ · daily
- Frequency
- Once daily, same or separate injections
- Primary benefit
- Nerve regeneration, pain reduction, tissue healing
VIP
— no documented stacks